Matthew Ku

1 week ago | cgtlive.com | Matthew Ku |Noah Stansfield |Ashling Wahner |Chris Ryan

Data from a phase 1b clinical trial (NCT05421663) evaluating Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, were presented at the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy.

1 week ago | cgtlive.com | Matthew Ku |Ashling Wahner |Chris Ryan

This video originally appeared on our sister site, OncLive®. "Overall, only 7 patients, or 28% of the recommended phase 2 dose group, reported a serious treatment emergent adverse event."Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, is currently being evaluated for the treatment of relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in a phase 1b clinical trial (NCT05421663).